
Live Biotherapeutic Products and Microbiome Manufacturing Market (2nd Edition), 2022-2035
Description
Live Biotherapeutic Products and Microbiome Manufacturing Market (2nd Edition), 2022-2035
Given the advancement of several promising microbiome-based live biotherapeutic products through clinical pipeline, this upcoming therapeutic segment is anticipated to become one of the fastest growing markets within the pharmaceutical industry in the coming years. Specifically, in 2020, around 575 IND applications were filed for such therapies, targeting a myriad of diseases indications, including autoimmune, gastrointestinal, infectious, metabolic and oncological disorders, indicating remarkable scientific progress of these breakthrough drug candidates. It is also worth highlighting that SER-109, a microbiome-based therapy developed by Seres Therapeutics, is expected to receive marketing approval from the US Food and Drug Administration (FDA) in 2022; this is further likely to propel the growth in this domain. Further, over 640 patents focused on microbiome therapeutics were granted approval in the year 2020. In addition, during the same time frame, USD 1.5 billion was invested for the development of microbiome-based therapeutics. Although a lot has been achieved in terms of development of live biotherapeutic products, there are certain challenges associated with the complexity of the process. Other key concerns shared by contemporary innovators include limited availability of expertise, lack of specialized infrastructure, requirement for exorbitant capital investment, and constraints associated with ensuring compliance to good manufacturing practices (GMP) and capacity. ,
In order to address the technical and operational challenges outlined above, several microbiome developers prefer to rely on contract manufacturing organizations (CMOs). It is worth highlighting that, currently, over 50 players engaged in the manufacturing of microbiome-related products carry out operations either in-house or on contract basis. The current market landscape of microbiome contract manufacturers is highly fragmented, featuring a mix of start-ups, mid-sized firms and established players. Moreover, in recent years, several players engaged in this domain have forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings and operate as one-stop-shops. As stakeholders strive to mitigate existing challenges and focus on innovation to improve the microbiome production process, we believe that the microbiome manufacturing market is expected to witness significant growth over the next decade.
SCOPE OF THE REPORT
The “Live Biotherapeutic Products and Microbiome Manufacturing Market by Type of Product Manufactured (API and FDF), Type of Formulation (Solids, Oral Liquids and Injectables), Type of Primary Packaging Used (Blister Packs, Glass / Plastic Bottles, Pouches / Sachets and Vials), Scale of Operation (Clinical and Commercial), Company Size (Small, Mid-sized and Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022 – 2035” report features an extensive study on the in- house and contract manufacturing organizations within the microbiome industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:
A detailed overview of the overall landscape of companies offering contract manufacturing services for the development of microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of fermentation (aerobic and anaerobic), type of formulation (solids, oral liquids and injectables), type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets, and vials), number and location of manufacturing facilities and bioprocessing capacity. Further, it provides a list of companies with in-house manufacturing facilities for microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities.
A detailed landscape of the live biotherapeutic products and microbiome manufacturing facilities established across key geographical regions (North America, Europe and Asia-Pacific), highlighting the key manufacturing hubs for microbiomes.
An in-depth company competitiveness analysis of microbiome manufacturing service providers based on their product portfolio strength (in terms of scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities), service strength (based on its experience) and type of service(s) offered.
Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics across both clinical and commercial scales of operation. Each profile features a brief overview of the company, details related to its microbiome-related service portfolio, microbiome manufacturing facilities, recent developments, and an informed future outlook.
A list of nearly 70 microbiome-focused drug developers that are likely to partner with manufacturers engaged in this domain. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of in-house manufacturing capabilities.
A review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.
An analysis of recent developments within the microbiome manufacturing industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
An in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions.
An estimate of the overall, installed capacity for the manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity based on the scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).
An informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
A qualitative analysis, highlighting various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
A case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on their year of establishment, company size and location of headquarters.
One of the key objectives of the report was to evaluate the current opportunity and the future potential of the microbiome manufacturing market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids and injectables), [C] type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets and vials) [D] scale of operation (clinical and commercial), [E] company size (small, mid-sized and large) and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market till 2035, the report also provides our independent view on technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
Who are the key players engaged in offering contract manufacturing services for microbiome therapeutics?
What are the key challenges faced by microbiome contract manufacturers?
Who are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?
What is the annual clinical demand for microbiome-based live biotherapeutics?
What is the current, installed contract manufacturing capacity for live biotherapeutics?
What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision in this field?
What are the various initiatives undertaken by big pharma players in this domain?
What percentage of live biotherapeutics manufacturing operations are outsourced to service providers?
How is the current and future market opportunity likely to be distributed across key market segments?
What are the anticipated future trends related to live biotherapeutics manufacturing?
CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbiome therapeutics manufacturing market and its likely evolution in the short-mid term and long term.
Chapter 3 provides a general introduction to the human microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the human microbiome project (HMP). Further, the chapter features the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.
Chapter 4 provides an overview of the microbiome contract manufacturing landscape. It includes information on over 25 contract manufacturers that claim to offer microbiome therapeutics manufacturing services. In addition, it features an in-depth analysis of these companies, based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of fermentation (aerobic and anaerobic), type of formulation (solids, oral liquids and injectables), type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets, and vials), number and location of manufacturing facilities and bioprocessing capacity. It also provides a list of companies with in-house manufacturing facilities for microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities.
Chapter 5 provides a detailed landscape of microbiome manufacturing facilities in key regions (North America, Europe and Asia-Pacific). It includes analysis and map representations based on location of these facilities, highlighting key provinces as the manufacturing hubs.
Chapter 6 features an insightful company competitiveness analysis of microbiome manufacturing service providers based on their product portfolio strength (scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities), service strength (based on its experience) and type of service(s) offered.
Chapter 7 includes detailed profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities, and recent developments and an informed future outlook.
Chapter 8 provides list of nearly 70 microbiome-focused drug developers that are anticipated to partner with manufacturers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of in-house manufacturing capabilities.
Chapter 9 presents a review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.
Chapter 10 presents detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the microbiome manufacturing industry, during the period between 2016 and 2021.
Chapter 11 features an in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions.
Chapter 12 provides an estimate of the overall, installed capacity for the manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).
Chapter 13 presents an informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
Chapter 14 provides a qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
Chapter 15 includes a case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on the year of establishment, company size and location of headquarters.
Chapter 16 presents an insightful market forecast analysis, highlighting the future potential of microbiome manufacturing market till 2035. We have segmented the market on the basis of [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids and injectables), [C] type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets and vials) [D] scale of operation (clinical and commercial), [E] company size (small, mid-sized and large) and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).
Chapter 17 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the microbiome contract manufacturing market, based on the research and analysis described in the previous chapters.
Chapter 18 is a collection of transcripts of interviews conducted with various stakeholders in the industry.
Chapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 20 is an appendix that provides the list of companies and organizations mentioned in the report.
LIST OF COMPANIES AND ORGANIZATIONS
The following companies / institutes / government bodies and organizations have been mentioned in this report.
1. 4D Pharma
2. AbbVie
3. ABCO Laboratories
4. ABH Pharma
5. Adare Pharmaceuticals
6. ADM Biopolis
7. Advanced Enzymes
8. Allianz Biosciences
9. AmpliPhi Biosciences
10. AOBiome Therapeutics
11. Arena Pharmaceuticals
12. Armata Pharmaceuticals
13. Arranta Bio
14. AsiaBiome
15. Assembly Biosciences
16. AstraZeneca
17. Atlantic Essential Products
18. Aumgene Biosciences
19. Axial Therapeutics
20. Azabu University
21. Azitra
22. BacThera
23. Biena
24. Bifodan
25. BIOASTER
26. BioCare
27. Biocodex
28. BioGaia
29. Biomar Microbial Technologies
30. Biomcare
31. Bio-Me
32. Biomica (a subsidary of Evogene)
33. Biomillenia
34. BiomX
35. Biose
36. Biosortia Pharmaceuticals
37. BJP Laboratories
38. Bloom Science
39. Blue Turtle Bio
40. Boehringer Ingelheim
41. Bristol-Myers Squibb
42. C3J Therapeutics
43. Caelus Health
44. Cambridge University Hospitals NHS Foundation Trust
45. Cancer Research UK
46. Capsugel
47. Captozyme
48. Cell Biotech
49. Cerbios-Pharma
50. CHAIN Biotechnology
51. Charles River Laboratories
52. Chr. Hansen
53. Clinical Microbiomics
54. ClostraBio
55. Commense (a subsidiary of PureTech Health)
56. CoreBiome
57. CosmosID
58. Crestovo
59. Custom Probiotics
60. Da Volterra
61. Debiopharm
62. Deerland Probiotics & Enzymes
63. DermBiont
64. Diversigen
65. DuPont
66. EirGenix
67. Emerge Health
68. EMF
69. Emulate
70. Enterin
71. EnteroBiotix
72. Enterome
73. Evelo Biosciences
74. Evologic Technologies
75. EXDEN
76. Exeliom Biosciences
77. Exim Pharma
78. Ferring Pharmaceuticals
79. Finch Therapeutics
80. FUJIFILM Diosynth Biotechnologies
81. Ganeden Biotech
82. GENIBIO (a subsidiary of the LARENA and GB ACTION)
83. Genome & Company
84. GI Innovation
85. Gilead Sciences
86. Ginkgo Bioworks
87. Gustave Roussy
88. Gusto Global
89. Heidelberg University
90. iCarbonX
91. Igen BioLab Group
92. ImmuneBiotech
93. Immuron
94. Infant Bacterial Therapeutics
95. Inpac Probiotics
96. Ion Labs
97. Jeneil Biotech
98. John Theurer Cancer Center
99. Johnson & Johnson
100. JW Nutritional
101. Kaleido Biosciences
102. Karolinska Institutet
103. Karyotica Biologicals
104. Kendy Pharma
105. Kibow Biotech
106. Lallemand
107. Leadiant Biosciences
108. Leiden University Medical Center
109. List Biological Laboratories
110. LNC Therapeutics
111. Locus Biosciences
112. Lonza
113. LUCA Biologics
114. Luina Bio
115. MaaT Pharma
116. Massachusetts General Hospital
117. MatriSys Bioscience
118. Mayo Clinic
119. Medella Naturals
120. Memorial Sloan Kettering Cancer Center
121. Merck
122. MeriCal
123. MetaboGen
124. Meteoric Biopharmaceuticals
125. Microba Life Sciences
126. Microbax
127. Microbiome Insights
128. MicrobiomeDx
129. Microbiotica
130. Microviable Therapeutics
131. Mirna Therapeutics
132. MRM Health
133. MSD
134. MyBiotics
135. Naked Biome
136. Nestlé Health Science
137. New Bellus
138. Nexbiome Therapeutics
139. NIZO
140. Norax Supplements
141. North Zealand University Hospital
142. Novartis
143. Novo Nordisk
144. NuBiyota
145. NutraScience Labs
146. NYU Grossman School of Medicine
147. Osel
148. OxThera
149. Parker Institute for Cancer Immunotherapy
150. Parkinson’s Institute and Clinical Center
151. Pfizer
152. Phi Therapeutics
153. Phylagen
154. Precigen ActoBio
155. Probi
156. ProbioFerm
157. Probiotical
158. Probiotics Australia
159. ProDigest
160. Protexin
161. Qu Biologics
162. Quay Pharma
163. Quorum Innovations
164. Rebiotix
165. The Research Institute of St
166. Resphera Biosciences
167. RIKEN
168. Rise Therapeutics
169. Roche
170. RondinX
171. Roswell Park Comprehensive Cancer Center
172. Sabinsa
173. Sacco
174. S-Biomedic
175. SciBac
176. Scioto Biosciences
177. Second Genome
178. Seres Therapeutics
179. SeylanMED
180. SFA Therapeutics
181. Siolta Therapeutics
182. Sirio Pharma
183. SNIPR Biome
184. Specialty Enzymes & Probiotics
185. Stanford Cancer Institute
186. Stanford University School of Medicine
187. Stellate Therapeutics
188. Symberix
189. Syngen Biotech
190. Synlogic
191. Synthetic Biologics
192. Takeda Pharmaceutical
193. The Medical University of Graz
194. The University of Texas MD Anderson Cancer Center
195. The University of Tokyo
196. Trayer Biotherapeutics
197. UAS Labs
198. Unique Biotech
199. University of Adelaide
200. University of Nottingham
201. University of Oxford
202. University of Pennsylvania
203. University of Reading
204. Vaiomer
205. Vedanta Biosciences
206. VITA-gen Laboratories
207. Vitakem
208. Wacker Biotech
209. Washington University School of Medicine
210. White Rock Capital Partners
211. Winclove Probiotics
212. Xycrobe Therapeutics (a subsidiary of Crown Laboratories)
213. Yakult Honsha
214. Zeta Farmaceutici
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Given the advancement of several promising microbiome-based live biotherapeutic products through clinical pipeline, this upcoming therapeutic segment is anticipated to become one of the fastest growing markets within the pharmaceutical industry in the coming years. Specifically, in 2020, around 575 IND applications were filed for such therapies, targeting a myriad of diseases indications, including autoimmune, gastrointestinal, infectious, metabolic and oncological disorders, indicating remarkable scientific progress of these breakthrough drug candidates. It is also worth highlighting that SER-109, a microbiome-based therapy developed by Seres Therapeutics, is expected to receive marketing approval from the US Food and Drug Administration (FDA) in 2022; this is further likely to propel the growth in this domain. Further, over 640 patents focused on microbiome therapeutics were granted approval in the year 2020. In addition, during the same time frame, USD 1.5 billion was invested for the development of microbiome-based therapeutics. Although a lot has been achieved in terms of development of live biotherapeutic products, there are certain challenges associated with the complexity of the process. Other key concerns shared by contemporary innovators include limited availability of expertise, lack of specialized infrastructure, requirement for exorbitant capital investment, and constraints associated with ensuring compliance to good manufacturing practices (GMP) and capacity. ,
In order to address the technical and operational challenges outlined above, several microbiome developers prefer to rely on contract manufacturing organizations (CMOs). It is worth highlighting that, currently, over 50 players engaged in the manufacturing of microbiome-related products carry out operations either in-house or on contract basis. The current market landscape of microbiome contract manufacturers is highly fragmented, featuring a mix of start-ups, mid-sized firms and established players. Moreover, in recent years, several players engaged in this domain have forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings and operate as one-stop-shops. As stakeholders strive to mitigate existing challenges and focus on innovation to improve the microbiome production process, we believe that the microbiome manufacturing market is expected to witness significant growth over the next decade.
SCOPE OF THE REPORT
The “Live Biotherapeutic Products and Microbiome Manufacturing Market by Type of Product Manufactured (API and FDF), Type of Formulation (Solids, Oral Liquids and Injectables), Type of Primary Packaging Used (Blister Packs, Glass / Plastic Bottles, Pouches / Sachets and Vials), Scale of Operation (Clinical and Commercial), Company Size (Small, Mid-sized and Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022 – 2035” report features an extensive study on the in- house and contract manufacturing organizations within the microbiome industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:
A detailed overview of the overall landscape of companies offering contract manufacturing services for the development of microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of fermentation (aerobic and anaerobic), type of formulation (solids, oral liquids and injectables), type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets, and vials), number and location of manufacturing facilities and bioprocessing capacity. Further, it provides a list of companies with in-house manufacturing facilities for microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities.
A detailed landscape of the live biotherapeutic products and microbiome manufacturing facilities established across key geographical regions (North America, Europe and Asia-Pacific), highlighting the key manufacturing hubs for microbiomes.
An in-depth company competitiveness analysis of microbiome manufacturing service providers based on their product portfolio strength (in terms of scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities), service strength (based on its experience) and type of service(s) offered.
Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics across both clinical and commercial scales of operation. Each profile features a brief overview of the company, details related to its microbiome-related service portfolio, microbiome manufacturing facilities, recent developments, and an informed future outlook.
A list of nearly 70 microbiome-focused drug developers that are likely to partner with manufacturers engaged in this domain. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of in-house manufacturing capabilities.
A review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.
An analysis of recent developments within the microbiome manufacturing industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
An in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions.
An estimate of the overall, installed capacity for the manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity based on the scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).
An informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
A qualitative analysis, highlighting various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
A case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on their year of establishment, company size and location of headquarters.
One of the key objectives of the report was to evaluate the current opportunity and the future potential of the microbiome manufacturing market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids and injectables), [C] type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets and vials) [D] scale of operation (clinical and commercial), [E] company size (small, mid-sized and large) and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market till 2035, the report also provides our independent view on technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
Who are the key players engaged in offering contract manufacturing services for microbiome therapeutics?
What are the key challenges faced by microbiome contract manufacturers?
Who are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?
What is the annual clinical demand for microbiome-based live biotherapeutics?
What is the current, installed contract manufacturing capacity for live biotherapeutics?
What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision in this field?
What are the various initiatives undertaken by big pharma players in this domain?
What percentage of live biotherapeutics manufacturing operations are outsourced to service providers?
How is the current and future market opportunity likely to be distributed across key market segments?
What are the anticipated future trends related to live biotherapeutics manufacturing?
CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbiome therapeutics manufacturing market and its likely evolution in the short-mid term and long term.
Chapter 3 provides a general introduction to the human microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the human microbiome project (HMP). Further, the chapter features the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.
Chapter 4 provides an overview of the microbiome contract manufacturing landscape. It includes information on over 25 contract manufacturers that claim to offer microbiome therapeutics manufacturing services. In addition, it features an in-depth analysis of these companies, based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of fermentation (aerobic and anaerobic), type of formulation (solids, oral liquids and injectables), type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets, and vials), number and location of manufacturing facilities and bioprocessing capacity. It also provides a list of companies with in-house manufacturing facilities for microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities.
Chapter 5 provides a detailed landscape of microbiome manufacturing facilities in key regions (North America, Europe and Asia-Pacific). It includes analysis and map representations based on location of these facilities, highlighting key provinces as the manufacturing hubs.
Chapter 6 features an insightful company competitiveness analysis of microbiome manufacturing service providers based on their product portfolio strength (scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities), service strength (based on its experience) and type of service(s) offered.
Chapter 7 includes detailed profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities, and recent developments and an informed future outlook.
Chapter 8 provides list of nearly 70 microbiome-focused drug developers that are anticipated to partner with manufacturers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of in-house manufacturing capabilities.
Chapter 9 presents a review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.
Chapter 10 presents detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the microbiome manufacturing industry, during the period between 2016 and 2021.
Chapter 11 features an in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions.
Chapter 12 provides an estimate of the overall, installed capacity for the manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).
Chapter 13 presents an informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
Chapter 14 provides a qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
Chapter 15 includes a case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on the year of establishment, company size and location of headquarters.
Chapter 16 presents an insightful market forecast analysis, highlighting the future potential of microbiome manufacturing market till 2035. We have segmented the market on the basis of [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids and injectables), [C] type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets and vials) [D] scale of operation (clinical and commercial), [E] company size (small, mid-sized and large) and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).
Chapter 17 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the microbiome contract manufacturing market, based on the research and analysis described in the previous chapters.
Chapter 18 is a collection of transcripts of interviews conducted with various stakeholders in the industry.
Chapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 20 is an appendix that provides the list of companies and organizations mentioned in the report.
LIST OF COMPANIES AND ORGANIZATIONS
The following companies / institutes / government bodies and organizations have been mentioned in this report.
1. 4D Pharma
2. AbbVie
3. ABCO Laboratories
4. ABH Pharma
5. Adare Pharmaceuticals
6. ADM Biopolis
7. Advanced Enzymes
8. Allianz Biosciences
9. AmpliPhi Biosciences
10. AOBiome Therapeutics
11. Arena Pharmaceuticals
12. Armata Pharmaceuticals
13. Arranta Bio
14. AsiaBiome
15. Assembly Biosciences
16. AstraZeneca
17. Atlantic Essential Products
18. Aumgene Biosciences
19. Axial Therapeutics
20. Azabu University
21. Azitra
22. BacThera
23. Biena
24. Bifodan
25. BIOASTER
26. BioCare
27. Biocodex
28. BioGaia
29. Biomar Microbial Technologies
30. Biomcare
31. Bio-Me
32. Biomica (a subsidary of Evogene)
33. Biomillenia
34. BiomX
35. Biose
36. Biosortia Pharmaceuticals
37. BJP Laboratories
38. Bloom Science
39. Blue Turtle Bio
40. Boehringer Ingelheim
41. Bristol-Myers Squibb
42. C3J Therapeutics
43. Caelus Health
44. Cambridge University Hospitals NHS Foundation Trust
45. Cancer Research UK
46. Capsugel
47. Captozyme
48. Cell Biotech
49. Cerbios-Pharma
50. CHAIN Biotechnology
51. Charles River Laboratories
52. Chr. Hansen
53. Clinical Microbiomics
54. ClostraBio
55. Commense (a subsidiary of PureTech Health)
56. CoreBiome
57. CosmosID
58. Crestovo
59. Custom Probiotics
60. Da Volterra
61. Debiopharm
62. Deerland Probiotics & Enzymes
63. DermBiont
64. Diversigen
65. DuPont
66. EirGenix
67. Emerge Health
68. EMF
69. Emulate
70. Enterin
71. EnteroBiotix
72. Enterome
73. Evelo Biosciences
74. Evologic Technologies
75. EXDEN
76. Exeliom Biosciences
77. Exim Pharma
78. Ferring Pharmaceuticals
79. Finch Therapeutics
80. FUJIFILM Diosynth Biotechnologies
81. Ganeden Biotech
82. GENIBIO (a subsidiary of the LARENA and GB ACTION)
83. Genome & Company
84. GI Innovation
85. Gilead Sciences
86. Ginkgo Bioworks
87. Gustave Roussy
88. Gusto Global
89. Heidelberg University
90. iCarbonX
91. Igen BioLab Group
92. ImmuneBiotech
93. Immuron
94. Infant Bacterial Therapeutics
95. Inpac Probiotics
96. Ion Labs
97. Jeneil Biotech
98. John Theurer Cancer Center
99. Johnson & Johnson
100. JW Nutritional
101. Kaleido Biosciences
102. Karolinska Institutet
103. Karyotica Biologicals
104. Kendy Pharma
105. Kibow Biotech
106. Lallemand
107. Leadiant Biosciences
108. Leiden University Medical Center
109. List Biological Laboratories
110. LNC Therapeutics
111. Locus Biosciences
112. Lonza
113. LUCA Biologics
114. Luina Bio
115. MaaT Pharma
116. Massachusetts General Hospital
117. MatriSys Bioscience
118. Mayo Clinic
119. Medella Naturals
120. Memorial Sloan Kettering Cancer Center
121. Merck
122. MeriCal
123. MetaboGen
124. Meteoric Biopharmaceuticals
125. Microba Life Sciences
126. Microbax
127. Microbiome Insights
128. MicrobiomeDx
129. Microbiotica
130. Microviable Therapeutics
131. Mirna Therapeutics
132. MRM Health
133. MSD
134. MyBiotics
135. Naked Biome
136. Nestlé Health Science
137. New Bellus
138. Nexbiome Therapeutics
139. NIZO
140. Norax Supplements
141. North Zealand University Hospital
142. Novartis
143. Novo Nordisk
144. NuBiyota
145. NutraScience Labs
146. NYU Grossman School of Medicine
147. Osel
148. OxThera
149. Parker Institute for Cancer Immunotherapy
150. Parkinson’s Institute and Clinical Center
151. Pfizer
152. Phi Therapeutics
153. Phylagen
154. Precigen ActoBio
155. Probi
156. ProbioFerm
157. Probiotical
158. Probiotics Australia
159. ProDigest
160. Protexin
161. Qu Biologics
162. Quay Pharma
163. Quorum Innovations
164. Rebiotix
165. The Research Institute of St
166. Resphera Biosciences
167. RIKEN
168. Rise Therapeutics
169. Roche
170. RondinX
171. Roswell Park Comprehensive Cancer Center
172. Sabinsa
173. Sacco
174. S-Biomedic
175. SciBac
176. Scioto Biosciences
177. Second Genome
178. Seres Therapeutics
179. SeylanMED
180. SFA Therapeutics
181. Siolta Therapeutics
182. Sirio Pharma
183. SNIPR Biome
184. Specialty Enzymes & Probiotics
185. Stanford Cancer Institute
186. Stanford University School of Medicine
187. Stellate Therapeutics
188. Symberix
189. Syngen Biotech
190. Synlogic
191. Synthetic Biologics
192. Takeda Pharmaceutical
193. The Medical University of Graz
194. The University of Texas MD Anderson Cancer Center
195. The University of Tokyo
196. Trayer Biotherapeutics
197. UAS Labs
198. Unique Biotech
199. University of Adelaide
200. University of Nottingham
201. University of Oxford
202. University of Pennsylvania
203. University of Reading
204. Vaiomer
205. Vedanta Biosciences
206. VITA-gen Laboratories
207. Vitakem
208. Wacker Biotech
209. Washington University School of Medicine
210. White Rock Capital Partners
211. Winclove Probiotics
212. Xycrobe Therapeutics (a subsidiary of Crown Laboratories)
213. Yakult Honsha
214. Zeta Farmaceutici
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Table of Contents
305 Pages
- 1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
- 2. EXECUTIVE SUMMARY
- 2.1. Chapter Overview
- 3. INTRODUCTION
- 3.1. Chapter Overview
- 3.2. Concept of Human Microbiota and Microbiome
- 3.3. Overview of Gut Flora
- 3.3.1. Role of Gut Flora in Healthy Individuals
- 3.3.2. Factors Affecting Human Gut Flora
- 3.4. The Human Microbiome Project (HMP)
- 3.5. Overview of Microbiome Therapies
- 3.5.1. Types of Microbiome Therapies
- 3.5.1.1. Probiotics
- 3.5.1.2. Prebiotics
- 3.5.2. Applications of Microbiome Therapies
- 3.5.3. Microbiome Therapies Supply Chain
- 3.6. Microbiome-based Product Manufacturing
- 3.6.1. Key Steps Involved
- 3.6.2. Associated Challenges
- 3.6.3. Role of Contract Manufacturing Organizations (CMOs)
- 3.6.4. Demand for Contract Manufacturing Services
- 3.7. Key Considerations while Selecting a Suitable CMO Partner
- 4. MARKET LANDSCAPE
- 4.1. Chapter Overview
- 4.2. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Market Landscape
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Location of Headquarters
- 4.2.4. Analysis by Scale of Operation
- 4.2.5. Analysis by Type of Product Manufactured
- 4.2.6. Analysis by Type of Formulation
- 4.2.7. Analysis by Scale of Operation and Type of Formulation
- 4.2.8. Analysis by Type of Primary Packaging Used
- 4.2.9. Analysis by Type of Formulation and Type of Primary Packaging Used
- 4.2.10. Analysis by Type of Fermentation
- 4.2.11. Analysis by Type of Fermentation and Location of Headquarters
- 4.2.12. Analysis by Type of Service(s) Offered
- 4.2.13. Analysis by Number of Manufacturing Facilities
- 4.2.14. Analysis by Location of Manufacturing Facilities
- 4.3. Live Biotherapeutic Products and Microbiome In-House Manufacturers: Market Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Scale of Operation
- 4.3.4. Analysis by Location of Headquarters
- 4.3.5. Analysis by Location of Manufacturing Facilities
- 5. REGIONAL CAPABILITY ANALYSIS
- 5.1. Chapter Overview
- 5.2. Key Assumptions and Methodology
- 5.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in North America
- 5.4. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in Europe
- 5.5. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in Asia-Pacific
- 6. COMPANY COMPETITIVENESS ANALYSIS
- 6.1. Chapter Overview
- 6.2. Key Assumptions and Parameters
- 6.3. Methodology
- 6.4. Company Competitiveness: North America
- 6.5. Company Competitiveness: Europe
- 6.6. Company Competitiveness: Asia-Pacific
- 6.7. Capability Benchmarking of Top Microbiome Contract Manufactures
- 7. COMPANY PROFILES
- 7.1. Chapter Overview
- 7.2. CMOs Headquartered in North America
- 7.2.1. Capsugel
- 7.2.1.1. Company Overview
- 7.2.1.2. Service Portfolio
- 7.2.1.3. Facilities Dedicated to Microbiome Manufacturing
- 7.2.1.4. Recent Developments and Future Outlook
- 7.2.2. Jeneil Biotech
- 7.2.2.1. Company Overview
- 7.2.2.2. Service Portfolio
- 7.2.2.3. Facilities Dedicated to Microbiome Manufacturing
- 7.2.2.4. Recent Developments and Future Outlook
- 7.2.3. UAS Labs
- 7.2.3.1. Company Overview
- 7.2.3.2. Service Portfolio
- 7.2.3.3. Facilities Dedicated to Microbiome Manufacturing
- 7.2.3.4. Recent Developments and Future Outlook
- 7.3. CMOs Headquartered in Europe
- 7.3.1. Biose
- 7.3.1.1. Company Overview
- 7.3.1.2. Service Portfolio
- 7.3.1.3. Facilities Dedicated to Microbiome Manufacturing
- 7.3.1.4. Recent Developments and Future Outlook
- 7.3.2. Cerbios-Pharma
- 7.3.2.1. Company Overview
- 7.3.2.2. Financial Information
- 7.3.2.3. Service Portfolio
- 7.3.2.4. Facilities Dedicated to Microbiome Manufacturing
- 7.3.2.5. Recent Developments and Future Outlook
- 7.3.3. Inpac Probiotics
- 7.3.3.1. Company Overview
- 7.3.3.2. Service Portfolio
- 7.3.3.3. Facilities Dedicated to Microbiome Manufacturing
- 7.3.3.4. Recent Developments and Future Outlook
- 7.3.4. NIZO
- 7.3.4.1. Company Overview
- 7.3.4.2. Service Portfolio
- 7.3.4.3. Facilities Dedicated to Microbiome Manufacturing
- 7.3.4.4. Recent Developments and Future Outlook
- 7.3.5 Winclove Probiotics
- 7.3.5.1. Company Overview
- 7.3.5.2. Service Portfolio
- 7.3.5.3. Facilities Dedicated to Microbiome Manufacturing
- 7.3.5.4. Recent Developments and Future Outlook
- 7.4. CMOs Headquartered in Asia-Pacific and Rest of the World
- 7.4.1. BJP Laboratories
- 7.4.1.1. Company Overview
- 7.4.1.2. Service Portfolio
- 7.4.1.3. Facilities Dedicated to Microbiome Manufacturing
- 7.4.1.4. Recent Developments and Future Outlook
- 8. LIKELY PARTNER ANALYSIS
- 8.1. Chapter Overview
- 8.2. Scoring Criteria and Key Assumptions
- 8.3. Scope and Methodology
- 8.4. Key Potential Strategic Partners for Live Biotherapeutic Products and Microbiome Manufacturers
- 8.4.1. Likely Partner Opportunities in North America
- 8.4.2. Likely Partner Opportunities in Europe
- 8.4.3. Likely Partner Opportunities in Asia-Pacific
- 9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
- 9.1. Chapter Overview
- 9.2. Scope and Methodology
- 9.3. Microbiome Related Initiatives of Big Pharmaceutical Players
- 9.3.1. Analysis by Portfolio Diversity
- 9.3.2. Analysis by Phase of Development
- 9.3.3. Analysis by Type of Therapy
- 9.3.4. Analysis by Type of Drug Molecule
- 9.3.5. Analysis by Target Therapeutic Areas
- 9.4. Benchmark Analysis of Big Pharmaceutical Players
- 9.4.1. Spider Web Analysis: AbbVie
- 9.4.2. Spider Web Analysis: AstraZeneca
- 9.4.3. Spider Web Analysis: Bristol-Myers Squibb
- 9.4.4. Spider Web Analysis: Johnson and Johnson
- 9.4.5. Spider Web Analysis: Merck
- 9.4.6. Spider Web Analysis: Novartis
- 9.4.7. Spider Web Analysis: Novo Nordisk
- 9.4.8. Spider Web Analysis: Pfizer
- 9.4.9. Spider Web Analysis: Roche
- 9.4.10. Spider Web Analysis: Takeda Pharmaceutical
- 9.5. Concluding Remarks
- 10. RECENT DEVELOPMENTS AND INITIATIVES
- 10.1. Chapter Overview
- 10.2. Partnership Models
- 10.3. Live Biotherapeutic Products and Microbiome: Recent Partnerships and Collaborations
- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Year and Type of Partnership
- 10.3.4. Analysis by Type of Organization
- 10.3.5. Analysis by Type of Partnership and Type of Organization
- 10.3.6. Analysis by Target Therapeutic Area
- 10.3.7. Most Active Players: Analysis by Number of Partnerships
- 10.3.8. Analysis by Region
- 10.3.8.1. Intracontinental and Intercontinental Agreements
- 10.3.8.2. Local and International Agreements
- 10.3.9. Cumulative Year-wise Trend of Merger / Acquisition
- 10.3.10. Analysis by Type of Acquisition
- 10.3.11. Analysis by Key Value Drivers
- 10.3.12. Analysis by Year of Acquisition and Key Value Drivers
- 10.4. Live Biotherapeutic Products and Microbiome: Recent Expansions
- 10.4.1. Analysis by Year of Expansion
- 10.4.2. Analysis by Purpose of Expansion
- 10.4.3. Analysis by Year and Purpose of Expansion
- 10.4.4. Analysis by Scale of Operation
- 10.4.5. Analysis by Purpose of Expansion and Scale of Operation
- 10.4.6. Analysis by Region
- 10.4.6.1. Analysis by Location of Manufacturing Facility (Continent-wise)
- 10.4.6.2. Analysis by Location of Manufacturing Facility (Country-wise)
- 10.4.7. Analysis by Purpose of Expansion and Location of Manufacturing Facility
- 11. CLINICAL TRIAL ANALYSIS
- 11.1. Chapter Overview
- 11.2. Scope and Methodology
- 11.3. Live Biotherapeutic Products and Microbiome: Clinical Trial Analysis
- 11.3.1. Analysis by Trial Registration Year
- 11.3.2. Analysis by Trial Status
- 11.3.3. Analysis by Trial Phase
- 11.3.4. Analysis by Trial Registration Year and Trial Recruitment Status
- 11.3.5. Analysis by Trial Registration Year and Enrolled Patient Population
- 11.3.6. Analysis by Study Design
- 11.3.7. Most Active Players: Analysis by Number of Registered Trials
- 11.3.7. Emerging Focus Area
- 11.3.9. Analysis by Therapeutic Area
- 11.3.10. Geographical Analysis by Number of Registered Trials
- 11.3.11. Geographical Analysis by Enrolled Patient Population
- 12. CAPACITY ANALYSIS
- 12.1. Chapter Overview
- 12.2. Key Assumptions and Methodology
- 12.3. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Global Production Capacity
- 12.3.1. Analysis by Company Size
- 12.3.2. Analysis by Scale of Operation
- 12.3.3. Analysis by Region
- 12.3.3.1. Capacity Analysis: North America
- 12.3.3.2. Capacity Analysis: Europe
- 12.3.3.3. Capacity Analysis: Asia-Pacific
- 12.4. Concluding Remarks
- 13. DEMAND ANALYSIS
- 13.1. Chapter Overview
- 13.2. Scope and Methodology
- 13.3. Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing
- 13.4. Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing
- 13.4.1. Geographical Analysis of Clinical Demand
- 13.4.1.1. Clinical Demand in North America
- 13.4.1.2. Clinical Demand in Europe
- 13.4.1.3. Clinical Demand in Asia-Pacific and Rest of the World
- 13.4.2. Analysis of Clinical Demand by Trial Phase
- 13.5. Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing
- 13.6. Concluding Remarks
- 14. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
- 14.1. Chapter Overview
- 14.2. Assumptions and Key Parameter
- 14.3. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Make versus Buy Decision Making
- 14.3.1. Scenario 1
- 14.3.2. Scenario 2
- 14.3.3. Scenario 3
- 14.3.4. Scenario 4
- 14.4. Concluding Remarks
- 15. CASE STUDY: LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT RESEARCH ORGANIZATIONS (CROs) AND DIETARY SUPPLEMENT MANUFACTURERS
- 15.1. Chapter Overview
- 15.2. Live Biotherapeutic Products and Microbiome CROs: Overall Market Landscape
- 15.2.1. Analysis by Year of Establishment
- 15.2.2. Analysis by Company Size
- 15.2.3. Analysis by Location of Headquarters
- 15.3. Microbiome Dietary Supplement Manufacturers: Overall Market Landscape
- 15.3.1. Analysis by Year of Establishment
- 15.3.2. Analysis by Company Size
- 15.3.3. Analysis by Location of Headquarters
- 16. MARKET FORECAST
- 16.1. Chapter Overview
- 16.2. Forecast Methodology
- 16.3. Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2022-2035
- 16.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Type of Product Manufactured
- 16.4.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for APIs, 2022-2035
- 16.4.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDFs, 2022-2035
- 16.5. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Type of Formulation
- 16.5.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Solid Formulations, 2022-2035
- 16.5.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Oral Liquids, 2022-2035
- 16.5.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Injectables, 2022-2035
- 16.5.4. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2022-2035
- 16.6. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Scale of Operation
- 16.6.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical Operations, 2022-2035
- 16.6.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial Operations, 2022-2035
- 16.7. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Company Size
- 16.7.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2022-2035
- 16.7.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2022-2035
- 16.7.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large Companies, 2022-2035
- 16.8. Microbiome Contract Manufacturing Market: Analysis by Geography
- 16.8.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America, 2022-2035
- 16.8.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe, 2022-2035
- 16.8.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2022-2035
- 16.9. Concluding Remarks
- 17. CONCLUSION
- 17.1. Chapter Overview
- 18. INTERVIEW TRANSCRIPTS
- 18.1. Chapter Overview
- 18.2. Traci Kyes, Vice President of Commercial Operations, Arranta Bio
- 18.2.1. Arranta Bio: Key Highlights
- 18.2.2. Interview Transcript
- 18.2. JP Benya, Vice President, Business Development, Assembly Biosciences
- 18.2.1. Assembly Biosciences: Key Highlights
- 18.2.2. Interview Transcript
- 18.3. Assaf Oron, Chief Business Officer, BiomX
- 18.3.1. BiomX: Key Highlights
- 18.3.2. Interview Transcript
- 18.4. Alexander Lin, Associate General Manager, Chung Mei Pharmaceutical
- 18.4.1. Chung Mei Pharmaceutical: Key Highlights
- 18.4.2. Interview Transcript
- 18.5. Debbie Pinkston, Vice President, Sales and Business Development, List Biological Laboratories
- 18.5.1. List Biological Laboratories: Key Highlights
- 18.5.2. Interview Transcript
- 18.6. Max Rosetto, Head of Business Development, Luina Bio
- 18.6.1. Luina Bio: Key Highlights
- 18.6.2. Interview Transcript
- 18.7. Gaurav Kaushik, Managing Director and Chief Executive Officer, Meteoric Biopharmaceuticals
- 18.7.1. Meteoric Biopharmaceuticals: Key Highlights
- 18.7.2. Interview Transcript
- 18.8. Veronika Oudova, Co-founder and Chief Executive Officer, S-Biomedic
- 18.8.1. S-Biomedic: Key Highlights
- 18.8.2. Interview Transcript
- 18.9. Nikole Kimes, Founder and Chief Executive Officer, Siolta Therapeutics
- 18.9.1. Siolta Therapeutics: Key Highlights
- 18.9.2. Interview Transcript
- 18.10. Alexander Segal, Vice President, Business Development, Universal Stabilization Technologies
- 18.10.1. Universal Stabilization Technologies: Key Highlights
- 18.10.2. Interview Transcript
- 18.11. Rob Van Dijk, Business Development Manager, Wacker Biotech
- 18.11.1. Wacker Biotech: Key Highlights
- 18.11.2. Interview Transcript
- 19. APPENDIX I: TABULATED DATA
- 20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
- LIST OF FIGURES
- Figure 2.1 Executive Summary: Overall Market Landscape
- Figure 2.2 Executive Summary: Recent Development and Initiatives
- Figure 2.3 Executive Summary: Capacity Analysis
- Figure 2.4 Executive Summary: Demand Analysis
- Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
- Figure 3.1 Key Benefits of Human Microbiota
- Figure 3.2 Factors Affecting the Gut Flora
- Figure 3.3 Human Microbiome Project: Key Achievements
- Figure 3.4 Microbiome Therapies: Design Approaches
- Figure 3.5 Types of Microbiome Therapies
- Figure 3.6 Probiotic Drugs: Overview of Beneficial Bacterial Strains
- Figure 3.7 Microbiome Therapies: Potential Application Areas
- Figure 3.8 Key Steps Involved in Microbiome Therapeutics Supply Chain
- Figure 3.9 Key Steps Involved in Microbiome Therapeutics Manufacturing
- Figure 3.10 Key Challenges in Manufacturing of Microbiome Therapeutics
- Figure 3.11 Key Strategies to Increase Efficiency in Manufacturing Microbiome Therapeutics
- Figure 3.12 Microbiome Manufacturing Industry Survey: Distribution by Respondent Particulars
- Figure 3.13 Microbiome Manufacturing Industry Survey: Distribution by Manufacturing Preference
- Figure 4.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
- Figure 4.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
- Figure 4.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
- Figure 4.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
- Figure 4.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
- Figure 4.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
- Figure 4.7 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
- Figure 4.8 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Primary Packaging Used
- Figure 4.9 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation and Type of Primary Packaging Used
- Figure 4.10 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Fermentation
- Figure 4.11 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Fermentation and Location of Headquarters
- Figure 4.12 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Service(s) Offered
- Figure 4.13 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Number of Manufacturing Facilities
- Figure 4.14 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Manufacturing Facilities
- Figure 4.15 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Year of Establishment
- Figure 4.16 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Company Size
- Figure 4.17 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Headquarters
- Figure 4.18 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Scale of Operation
- Figure 4.19 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Manufacturing Facilities
- Figure 5.1 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
- Figure 5.2 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
- Figure 5.3 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
- Figure 6.1 Company Competitiveness: Distribution of Players based in North America
- Figure 6.2 Company Competitiveness: Distribution of Players based in Europe
- Figure 6.3 Company Competitiveness: Distribution of Players based in Asia-Pacific
- Figure 6.4 Company Competitiveness: Distribution of Top 10 Players (Wind Rose Representation)
- Figure 7.1 Capsugel: Service Portfolio
- Figure 7.2 Jeneil Biotech: Service Portfolio
- Figure 7.3 UAS Labs: Service Portfolio
- Figure 7.4 Biose: Service Portfolio
- Figure 7.5 Cerbios-Pharma: Service Portfolio
- Figure 7.6 Inpac Probiotics: Service Portfolio
- Figure 7.7 NIZO: Service Portfolio
- Figure 7.8 Winclove Probiotics: Service Portfolio
- Figure 7.9 BJP Laboratories: Service Portfolio
- Figure 9.1 Big Pharma Players: Distribution of Top Pharmaceutical Companies (Heat Map Representation)
- Figure 9.2 Big Pharma Players: Distribution by Portfolio Diversity
- Figure 9.3 Big Pharma Players: Distribution by Phase of Development
- Figure 9.4 Big Pharma Players: Distribution by Type of Therapy
- Figure 9.5 Big Pharma Players: Distribution by Type of Drug Molecule
- Figure 9.6 Big Pharma Players: Distribution by Target Therapeutic Areas
- Figure 9.7 Spider Web Analysis: AbbVie
- Figure 9.8 Spider Web Analysis: AstraZeneca
- Figure 9.9 Spider Web Analysis: BMS
- Figure 9.10 Spider Web Analysis: Johnson and Johnson
- Figure 9.11 Spider Web Analysis: Merck
- Figure 9.12 Spider Web Analysis: Novartis
- Figure 9.13 Spider Web Analysis: Novo Nordisk
- Figure 9.14 Spider Web Analysis: Pfizer
- Figure 9.15 Spider Web Analysis: Roche
- Figure 9.16 Spider Web Analysis: Takeda Pharmaceutical
- Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership
- Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
- Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
- Figure 10.4 Partnerships and Collaborations: Distribution by Type of Organization
- Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Organization
- Figure 10.6 Partnerships and Collaborations: Distribution by Therapeutic Area
- Figure 10.7 Most Active Players: Distribution by Number of Partnerships
- Figure 10.8 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
- Figure 10.9 Partnerships and Collaborations: Local and International Agreements
- Figure 10.10 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
- Figure 10.11 Mergers and Acquisitions: Distribution by Key Value Drivers
- Figure 10.12 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
- Figure 10.13 Recent Expansions: Distribution by Year of Expansion
- Figure 10.14 Recent Expansions: Distribution by Purpose of Expansion
- Figure 10.15 Recent Expansions: Distribution by Year and Purpose of Expansion
- Figure 10.16 Recent Expansions: Distribution by Scale of Operation
- Figure 10.17 Recent Expansions: Distribution by Purpose of Expansion and Scale of Operation
- Figure 10.18 Recent Expansions: Distribution by Location of Manufacturing Facility (Continent-wise)
- Figure 10.19 Recent Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
- Figure 10.20 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
- Figure 11.1 Clinical Trial Analysis: Scope and Methodology
- Figure 11.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2021
- Figure 11.3 Clinical Trial Analysis: Distribution by Trial Status
- Figure 11.4 Clinical Trial Analysis: Distribution by Trial Phase
- Figure 11.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status, Pre-2013-2021
- Figure 11.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2021
- Figure 11.7 Clinical Trial Analysis: Distribution by Study Design
- Figure 11.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
- Figure 11.9 Most Active Players: Distribution by Number of Registered Trials
- Figure 11.10 Clinical Trial Analysis: Emerging Focus Areas
- Figure 11.11 Clinical Trial Analysis: Distribution by Therapeutic Area
- Figure 11.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
- Figure 11.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
- Figure 12.1 Capacity Analysis: Distribution by Company Size
- Figure 12.2 Capacity Analysis: Distribution by Scale of Manufacturing
- Figure 12.3 Capacity Analysis: Distribution by Region
- Figure 12.4 Capacity Analysis: Microbiome Contract Manufacturing Capacity in North America
- Figure 12.5 Capacity Analysis: Microbiome Contract Manufacturing Capacity in Europe
- Figure 12.6 Capacity Analysis: Microbiome Contract Manufacturing Capacity in Asia-Pacific
- Figure 13.1 Global Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Patients)
- Figure 13.2 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Trials Conducted)
- Figure 13.3 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Enrolled Patients)
- Figure 13.4 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Distribution by Geography
- Figure 13.5 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in North America, 2022-2031 (Number of Enrolled Patients)
- Figure 13.6 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in Europe, 2022-2031 (Number of Enrolled Patients)
- Figure 13.7 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2022-2031 (Number of Enrolled Patients)
- Figure 13.8 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Distribution by Trial Phase, 2022-2031 (Number of Enrolled Patients)
- Figure 13.9 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Target Patient Population)
- Figure 14.1 Make versus Buy Decision Making Framework
- Figure 14.2 Make versus Buy Decision Making: Possible Scenario Descriptions
- Figure 15.1 Live Biotherapeutic Products and Microbiome CROs: Distribution by Year of Establishment
- Figure 15.2 Live Biotherapeutic Products and Microbiome CROs: Distribution by Company Size
- Figure 15.3 Live Biotherapeutic Products and Microbiome CROs: Distribution by Location of Headquarters
- Figure 15.4 Microbiome Dietary Supplement Manufacturers: Distribution by Year of Establishment
- Figure 15.5 Microbiome Dietary Supplement Manufacturers: Distribution by Company Size
- Figure 15.6 Microbiome Dietary Supplement Manufacturers: Distribution by Location of Headquarters
- Figure 16.1 Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2022-2035 (USD Million)
- Figure 16.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Product Manufactured.
- Figure 16.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for APIs, 2022-2035 (USD Million)
- Figure 16.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDFs, 2022-2035 (USD Million)
- Figure 16.5 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Formulation
- Figure 16.6 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Solid Formulations, 2022-2035 (USD Million)
- Figure 16.7 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Oral Liquids, 2022-2035 (USD Million)
- Figure 16.8 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Injectables, 2022-2035 (USD Million)
- Figure 16.9 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2022-2035 (USD Million)
- Figure 16.10 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Scale of Operation
- Figure 16.11 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical Operations, 2022-2035 (USD Million)
- Figure 16.12 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial Operations, 2022-2035 (USD Million)
- Figure 16.13 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Company Size
- Figure 16.14 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2022-2035 (USD Million)
- Figure 16.15 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2022-2035 (USD Million)
- Figure 16.16 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large Companies, 2022-2035 (USD Million)
- Figure 16.17 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Geography
- Figure 16.18 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America, 2022-2035 (USD Million)
- Figure 16.19 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe, 2022-2035 (USD Million)
- Figure 16.20 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
- Figure 17.1 Concluding Remarks: Overall Market Landscape
- Figure 17.2 Concluding Remarks: Recent Development and Initiatives
- Figure 17.3 Concluding Remarks: Capacity Analysis
- Figure 17.4 Concluding Remarks: Demand Analysis
- Figure 17.5 Concluding Remarks: Market Forecast and Opportunity Analysis
- Figure 17.6 Concluding Remarks: Market Forecast and Opportunity Analysis
- LIST OF TABLES
- Table 3.1 Different Types of Microbiota in the Gastrointestinal Tract
- Table 3.2 Various Food Items Containing Prebiotics
- Table 3.3 Harvey Ball Analysis: Comparison of Key Factors for the Selection of CMOs
- Table 4.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Market Landscape
- Table 4.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Product Manufactured
- Table 4.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Formulation
- Table 4.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Primary Packaging Used
- Table 4.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Fermentation
- Table 4.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Service(s) Offered
- Table 4.7 Live Biotherapeutic Products and Contract Manufacturers: Information on Manufacturing Facilities
- Table 4.8 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Market Landscape
- Table 7.1 Capsugel: Company Overview
- Table 7.2 Jeneil Biotech: Company Overview
- Table 7.3 UAS Labs: Company Overview
- Table 7.4 UAS Labs: Recent Developments and Future Outlook
- Table 7.5 Biose: Company Overview
- Table 7.6 Biose: Recent Developments and Future Outlook
- Table 7.7 Cerbios-Pharma: Company Overview
- Table 7.8 Inpac Probiotics: Company Overview
- Table 7.9 NIZO: Company Overview
- Table 7.10 Winclove Probiotics: Company Overview
- Table 7.11 Winclove Probiotics: Recent Developments and Future Outlook
- Table 7.12 BJP Laboratories: Company Overview
- Table 8.1 Likely Partners for Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
- Table 8.2 Likely Partners for Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
- Table 8.3 Likely Partners for Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
- Table 10.1 Live Biotherapeutic Products and Microbiome: List of Partnerships and Collaborations, 2016-2021
- Table 10.2 Live Biotherapeutic Products and Microbiome Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), 2016-2021
- Table 10.3 Mergers and Acquisitions: Information on Key Value Drivers, 2016-2021
- Table 10.4 Live Biotherapeutic Products and Microbiome: List of Recent Expansions, 2019- 2020
- Table 12.1 Capacity Analysis: Average Capacity per Category
- Table 12.2 Capacity Analysis: Global Contract Microbiome Manufacturing Capacity
- Table 13.1 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Information on Number of Enrolled Patients by Trial Phase
- Table 13.2 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Information on Phase III Microbiome-based Live Biotherapeutic Products
- Table 16.1 Live Biotherapeutic Products and Microbiome CROs
- Table 16.2 Microbiome Dietary Supplement Manufacturers
- Table 19.1 Arranta Bio: Key Highlights
- Table 19.2 Assembly Biosciences: Key Highlights
- Table 19.3 BiomX: Key Highlights
- Table 19.4 Chung Mei Pharmaceutical: Key Highlights
- Table 19.5 List Biological Laboratories: Key Highlights
- Table 19.6 Luina Bio: Key Highlights
- Table 19.7 Meteoric Biopharmaceuticals: Key Highlights
- Table 19.8 S-Biomedic: Key Highlights
- Table 19.9 Siolta Therapeutics: Key Highlights
- Table 19.10 Universal Stabilization Technologies: Key Highlights
- Table 19.11 Wacker Biotech: Key Highlights
- Table 20.1 Microbiome Manufacturing Industry Survey: Distribution by Respondent Particulars
- Table 20.2 Microbiome Manufacturing Industry Survey: Distribution by Manufacturing Preference
- Table 20.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
- Table 20.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
- Table 20.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
- Table 20.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
- Table 20.7 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Product Manufactured
- Table 20.8 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
- Table 20.9 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
- Table 20.10 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Primary Packaging Used
- Table 20.11 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation and Type of Primary Packaging Used
- Table 20.12 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Fermentation
- Table 20.13 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Fermentation and Location of Headquarters
- Table 20.14 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Service(s) Offered
- Table 20.15 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Number of Manufacturing Facilities
- Table 20.16 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Manufacturing Facilities
- Table 20.17 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Year of Establishment
- Table 20.18 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Company Size
- Table 20.19 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Headquarters
- Table 20.20 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Scale of Operation
- Table 20.21 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Manufacturing Facilities
- Table 20.22 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
- Table 20.23 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
- Table 20.24 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
- Table 20.25 Partnerships and Collaborations: Distribution by Year of Partnership
- Table 20.26 Partnerships and Collaborations: Distribution by Type of Partnership
- Table 20.27 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
- Table 20.28 Partnerships and Collaborations: Distribution by Type of Organization
- Table 20.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Organization
- Table 20.30 Partnerships and Collaborations: Distribution by Therapeutic Area
- Table 20.31 Most Active Players: Distribution by Number of Partnerships
- Table 20.32 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
- Table 20.33 Partnerships and Collaborations: Local and International Agreements
- Table 20.34 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
- Table 20.35 Mergers and Acquisitions: Distribution by Key Value Drivers
- Table 20.36 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
- Table 20.37 Recent Expansions: Distribution by Year of Expansion
- Table 20.38 Recent Expansions: Distribution by Purpose of Expansion
- Table 20.39 Recent Expansions: Distribution by Year and Purpose of Expansion
- Table 20.40 Recent Expansions: Distribution by Scale of Operation
- Table 20.41 Recent Expansions: Distribution by Purpose of Expansion and Scale of Operation
- Table 20.42 Recent Expansions: Distribution by Location of Manufacturing Facility (Continent-wise)
- Table 20.43 Recent Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
- Table 20.44 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
- Table 20.45 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2021
- Table 20.46 Clinical Trial Analysis: Distribution by Trial Status
- Table 20.47 Clinical Trial Analysis: Distribution by Trial Phase
- Table 20.48 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status, Pre-2013-2021
- Table 20.49 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2021
- Table 20.50 Clinical Trial Analysis: Distribution by Study Design
- Table 20.51 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
- Table 20.52 Most Active Players: Distribution by Number of Registered Trials
- Table 20.53 Clinical Trial Analysis: Distribution by Therapeutic Area
- Table 20.54 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
- Table 20.55 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
- Table 20.56 Capacity Analysis: Distribution by Company Size
- Table 20.57 Capacity Analysis: Distribution by Scale of Manufacturing
- Table 20.58 Capacity Analysis: Distribution by Region
- Table 20.59 Capacity Analysis: Microbiome Contract Manufacturing Capacity in North America
- Table 20.60 Capacity Analysis: Microbiome Contract Manufacturing Capacity in Europe
- Table 20.61 Capacity Analysis: Microbiome Contract Manufacturing Capacity in Asia-Pacific
- Table 20.62 Global Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Patients)
- Table 20.63 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Trials Conducted)
- Table 20.64 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Enrolled Patients)
- Table 20.65 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Distribution by Geography
- Table 20.66 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in North America, 2022-2031 (Number of Enrolled Patients)
- Table 20.67 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in Europe, 2022-2031 (Number of Enrolled Patients)
- Table 20.68 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2022-2031 (Number of Enrolled Patients)
- Table 20.69 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Distribution by Trial Phase, 2022-2031 (Number of Enrolled Patients)
- Table 20.70 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Target Patient Population)
- Table 20.71 Live Biotherapeutic Products and Microbiome CROs: Distribution by Year of Establishment
- Table 20.72 Live Biotherapeutic Products and Microbiome CROs: Distribution by Company Size
- Table 20.73 Live Biotherapeutic Products and Microbiome CROs: Distribution by Location of Headquarters
- Table 20.74 Microbiome Dietary Supplement Manufacturers: Distribution by Year of Establishment
- Table 20.75 Microbiome Dietary Supplement Manufacturers: Distribution by Company Size
- Table 20.76 Microbiome Dietary Supplement Manufacturers: Distribution by Location of Headquarters
- Table 20.77 Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2022-2035 (USD Million)
- Table 20.78 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Product Manufactured.
- Table 20.79 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for APIs, 2022-2035 (USD Million)
- Table 20.80 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDFs, 2022-2035 (USD Million)
- Table 20.81 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Formulation
- Table 20.82 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Solid Formulations, 2022-2035 (USD Million)
- Table 20.83 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Oral Liquids, 2022-2035 (USD Million)
- Table 20.84 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Injectables, 2022-2035 (USD Million)
- Table 20.85 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2022-2035 (USD Million)
- Table 20.86 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Scale of Operation
- Table 20.87 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical Operations, 2022-2035 (USD Million)
- Table 20.88 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial Operations, 2022-2035 (USD Million)
- Table 20.89 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Company Size
- Table 20.90 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2022-2035 (USD Million)
- Table 20.91 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2022-2035 (USD Million)
- Table 20.92 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large Companies, 2022-2035 (USD Million)
- Table 20.93 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Geography
- Table 20.94 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America, 2022-2035 (USD Million)
- Table 20.95 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe, 2022-2035 (USD Million)
- Table 20.96 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.